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Abstract
The transcription factor, nuclear factor κB (NF-κB), plays a central role as a key mediator of cell survival and prolifer-
ation, and its activation may confer increased tumor chemoresistance. Curcumin, an orally available naturally occur-
ring compound, has been shown to inhibit NF-κB and has a potential role in cancer chemoprevention.We investigated
the effects of curcumin on NF-κB activity, on cell viability, and as a chemosensitizing agent with 5-fluorouracil (5-FU)
or cisplatin (CDDP) in esophageal adenocarcinoma (EAC). Oligonucleotide microarray analysis of 46 cases, consist-
ing of Barrett metaplasia, low-grade dysplasia, high-grade dysplasia and EAC, showed increased expression of
NF-κB and IκB kinase subunits and decreased effector caspase expression in EAC compared with Barrett meta-
plasia. Stromal expression of both IκB and phospho-IκB was detected in several EAC samples by tissue microarray
analysis. Curcumin alone inhibited NF-κB activity and induced apoptosis in both Flo-1 and OE33 EAC cell lines as
determined by Western blot analysis, NF-κB reporter assays, and Caspase–Glo 3/7 assays. It also increased 5-FU–
and CDDP-induced apoptosis in both cell lines. These data suggest that activation of NF-κB and inhibition of apop-
tosis may play a role in the progression from Barrett metaplasia to EAC. In addition, curcumin, a well-known inhibitor
of NF-κB activity, was shown to increase apoptosis and enhance both 5-FU– and CDDP-mediated chemosensitivity,
suggesting that it may have potential application in the therapy of patients with EAC.
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Introduction
The incidence of esophageal adenocarcinoma (EAC) has increased
significantly, especially in western countries. Surveillance, Epidemiol-
ogy, and End Results (SEER) registry data indicate a three- to four-
fold increase in incidence during the past 30 years [1], with current
estimates of approximately 7000 new cases per year in the United
States alone. EAC is generally diagnosed at a late stage and has a poor
prognosis, with a 5-year survival of less than 10%. Although the cur-
rent treatment includes chemotherapy, radiation therapy, and, if pos-
sible, esophagogastric resection, many patients with EAC experience
progression of disease despite such treatment, suggesting that such
tumors are resistant to chemotherapy.
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Nuclear factor κB (NF-κB) is a transcription factor that is associ-
ated with tumorigenesis, and its increased activity has been associated
with evasion of apoptosis, malignant transformation, sustained cell
proliferation, metastasis, and angiogenesis [2]. NF-κB is a protein
complex composed of several subunits including p50, p52, RelA
(p65), RelB, and c-Rel that dimerize, with the most common form
being the p50/RelA heterodimer. Inactive NF-κB is retained in the
cytoplasm by its interaction with inhibitors of κB (IκBα, IκBβ, or
IκBɛ) [3]. Activation of extrinsic pathway-mediated apoptosis is ini-
tiated by extracellular signaling such as that mediated by tumor ne-
crosis factor-α (TNFα) [4]. Resultant phosphorylation of IκB, its
subsequent ubiquitination and proteasome-mediated degradation re-
leases NF-κB, which then translocates to the nucleus [2].
Activation of NF-κB has been reported in several epithelial can-
cers, including breast [5–7], pancreas [8], oropharynx [9], lung [10],
and esophagus [11]. Increased bile acid exposure and an acidic envi-
ronment have been shown to induce NF-κB in dysplastic Barrett
esophagus, the precursor to EAC [12]. With its central role as a tran-
scription factor in a number of malignancies, NF-κB is a target for
ongoing development of novel targeted pharmacotherapy.
Curcumin, a phytopolyphenolic pigment derived from turmeric
(Curcuma longa), has been shown to have multiple anticancer effects,
including inhibition of proliferation, induction of apoptosis, inhibi-
tion of angiogenesis, and inhibition of DNA topoisomerase II. A
variety of mechanisms has been implicated as mediators of these
effects. Specifically, inhibition of activator protein 1 (AP-1), c-Jun
N-terminal kinase, Akt, and NF-κB signaling pathways has been de-
scribed [13,14]. Curcumin has been reported to inhibit NF-κB acti-
vation by suppressing the IκB kinases (IKKs), thereby resulting in
decreased proliferation and increased apoptosis [15,16]. It seems to
suppress constitutively active NF-κB in a variety of cancers [17]. Al-
though several clinical studies are in progress to evaluate the chemo-
therapeutic activity of curcumin in various cancers (www.cancer.gov/
clinicaltrials, accessed November 21, 2009), none have investigated
the effectiveness of curcumin in the treatment of EAC. Its pharma-
cology has been extensively studied, and data support the feasibility
of evaluating the efficacy of its oral administration in further clinical
trials for the treatment of gastrointestinal tract lesions [18].
We report in the present study that there is increased gene expression
of NF-κB and IKK subunits and decreased expression of apoptosis-
effector genes in primary EAC samples compared with Barrett meta-
plasia. We demonstrate that curcumin inhibits NF-κB activity and
promotes apoptosis in EAC cell lines, as has been demonstrated in
other types of epithelial malignancies [8,9,13,17]. We also show that
curcumin can enhance the in vitro cytotoxicity of 5-fluorouracil (5-FU)
and cisplatin (CDDP), two first-line chemotherapeutic agents used in
the treatment of EAC.
Materials and Methods
Patients and Tissues
After obtaining informed consent, tissues were obtained from pa-
tients undergoing esophagectomy for adenocarcinoma at the Univer-
sity of Michigan Medical Center (Ann Arbor, MI) and transported to
the laboratory in Dulbecco’s modified Eagle medium (Invitrogen,
Carlsbad, CA) on ice. A portion of each sample was embedded in
OCT compound (Miles, Inc, Elkhart, IN) and frozen in isopentane
cooled in liquid nitrogen for cryostat sectioning. The remainder was
frozen in liquid nitrogen and stored at −80°C. Metaplastic or dysplas-
tic mucosa and tumor samples with at least 70% cellularity were
identified using hematoxylin and eosin–stained frozen sections, and
2-mm3 samples were obtained for RNA and protein isolation. The
sections were then examined by two pathologists to confirm the histo-
pathologic diagnosis of EAC, high-grade or low-grade dysplasia,
Barrett metaplasia, or normal esophageal mucosa. None of the pa-
tients had received previous chemotherapy or radiotherapy.
Cell Lines
OE33 (European Collection of Cell Cultures, Sigma-Aldrich,
St Louis, MO) and Flo-1 cell lines [19,20] were derived from EACs
and grown inRPMI orDulbecco’s modified Eaglemedium (Invitrogen),
respectively, supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Norcross, GA) and 1% penicillin/streptomycin/fungizone
(Invitrogen) and incubated at 37°C in 5% CO2/95% air.
Reagents
Curcumin was obtained from Sigma-Aldrich (catalog no. C7727),
diluted in dimethyl sulfoxide (DMSO, catalog no. D4540; Sigma-
Aldrich) to 100 mM and kept at −20°C. TNFα (catalog no. 2169;
Cell Signaling, Danvers, MA) was used to stimulate NF-κB. CDDP
(catalog no. P4394; Sigma-Aldrich) and 5-FU (catalog no. F6627;
Sigma-Aldrich) were used in chemosensitivity experiments.
Oligonucleotide Microarray
Oligonucleotide expression microarray analysis was performed as
previously described [21]. Briefly, total RNA was isolated from 46
esophageal samples using TRIzol (Invitrogen) and purified with
RNeasy spin columns (Qiagen, Valencia, CA) according to the man-
ufacturer’s instructions. RNA quality was assessed by 1% agarose gel
electrophoresis and A260/A280 spectrophotometer ratios. RNA quality
was reassessed with Agilent Bioanalyzer (Agilent Technologies, Palo
Alto, CA) at intermediate steps after double-stranded complementary
DNA and RNA (cDNA and cRNA, respectively) syntheses. cDNA
synthesis, cRNA amplification, hybridization, and washing of HG-
U133A gene chips (Affymetrix, Santa Clara, CA) were performed
by the University of Michigan Cancer Center Microarray Core ac-
cording to the manufacturer’s instructions.
To normalize microarray data, a summary statistic was calculated
using 11 probe pairs for each gene and the robust multichip average
method as implemented in the Affymetrix Library of Bioconductor
(version 1.3, www.bioconductor.org), which provides adjustment,
quantile normalization, and summarization. Expression values for
each sample were then compared with the mean expression value
for the seven Barrett metaplasia samples [22]. Hierarchical cluster
analysis and gene expression “heat maps” were generated using the
method of Eisen et al. [23].
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total RNA from treated cells was isolated and column purified
using the RNeasy Mini Kit (Qiagen) as per the manufacturer’s in-
structions and was then reverse-transcribed with 250 μM dNTPs,
12.5 ng/μl oligo(dT)12-18 primer, 75 ng/μl random primers, 10 mM
dithiothreitol, 1 U/μl RNaseOUT, and 5 U/μl SuperScript II reverse
transcriptase (Invitrogen). Real-time polymerase chain reaction (PCR)
amplification using 20 ng worth of total RNA, 1 × Platinum SYBR
Green qPCR SuperMix-UDG (Invitrogen), and 0.2 μMboth forward
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and reverse primers was performed on the Corbett Rotor-Gene 6000
(Qiagen). The following cycling parameters were used: 50°C hold
for 2 minutes; 95°C hold for 2 minutes; 40 cycles of 95°C for 10 sec-
onds, annealing for 15 seconds, and 72°C for 20 seconds. Signifi-
cant differences of relative quantification were determined using the
2(−ΔΔC (T)) method [24]. These data are represented as the fold in-
crease in gene expression normalized to the endogenous reference gene,
β2-microglobulin (B2M ).
Primer sets (Invitrogen) were designed using DNASTAR software
(Madison, WI).
Casp7: forward, 5′-TTCCGAAGCCTGGGTTTTGACG-3′;
and reverse, 5′-GCGAAGCAGGCGGCATTTGTA-3′
RelA: forward, 5′-GACCCCGGCCATGGACGAAC-3′; and
reverse, 5′-CCGCTGCTTGGGCTGCTCA-3′.
B2M: forward, 5′-GCTGTGCTCGCGCTACTCTC-3′; and
reverse, 5′-CAATGTCGGATGGATGAAACC-3′.
Immunohistochemistry and Tissue Microarray
The expression of IKK and Ser-32 phosphorylated IKK was de-
termined using an esophageal tissue microarray (TMA) [25,26] from
73 patients including 64 tumor, 8 lymph node metastases, 8 dysplas-
tic Barrett mucosa, and 11 nondysplastic Barrett metaplasia samples.
Normal esophagus was also included. Immunohistochemical staining
was performed on the DAKO Autostainer and the DAKO EnVision+
System, Peroxidase (DAKO, Carpinteria, CA). Microwave epitope
retrieval in 1 mM EDTA (pH 8) was performed for 20 minutes. De-
waxed and rehydrated sections of the TMA at 4-mm thickness were
labeled with IκB (1:100, catalog no. 9242; Cell Signaling) or phos-
phorylated IκB (Ser 32, 1:100, catalog no. 9241; Cell Signaling).
Slides were lightly counterstained with hematoxylin.
TNFα-Mediated Stimulation of NF-κB
To determine the optimal dosage for TNFα-mediated stimulation
of NF-κB, Flo-1 and OE33 cells were treated with TNFα at 0.1, 0.5,
1, 5, 7.5, and 10 ng/ml for 5, 15, 30, 60, 120, 240, and 480 minutes.
Cellular Proliferation and Chemosensitivity Assay
Cellular proliferation was determined by WST-1 assay (Roche Di-
agnostics, Indianapolis, IN), in accordance with the manufacturer’s di-
rections, with varying concentrations of curcumin, 5-FU, or CDDP.
Western Blot Analysis for Apoptosis and NF-κB Activity
Cells were plated at a density of 1.4 × 106 cells/60-mm plate and
allowed to adhere for 24 hours. Cells were treated with curcumin at
6.25, 12.5, 25, 50, or 100 μM for 48 hours. Untreated and DMSO
(100 μM)-treated cells were used as controls. In addition, cells ob-
served for NF-κB activity were treated with curcumin for 48 hours at
varying doses and then stimulated by TNFα at 10 ng/ml for 5 min-
utes. In separate experiments, Flo-1 and OE33 cell lines were treated
with combinations of curcumin and either 5-FU or CDDP.
Total cellular protein was extracted in lysis buffer (150 mM NaCl,
20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 2.5 mM
Na4P2O7, 1 mM β-glycerol phosphate, 1 mM Na3VO4, 1 μg/ml leu-
peptin, and 1% Triton X-100) supplemented with additional pro-
tease inhibitor cocktail (catalog no. P8340; Sigma-Aldrich). Lysates
(40 μg) were separated by electrophoresis in an 8% to 16% gradient
Tris-glycine gel (Invitrogen), then transferred to Immobilon-P nylon
membranes (Millipore, Bedford, MA). Membranes were blocked
with 5% evaporated milk in 1 × TBS/0.1% Tween 20 (TBST) for
1 hour at room temperature.
Primary antibodies against polyadenosine-5′-diphosphate-ribose
polymerase 1 (PARP) (1:1000, catalog no. 9542; Cell Signaling), IκBα
(1:1000, catalog no. 4812; Cell Signaling), phospho-IκBα (1:1000,
catalog no. 9246; Cell Signaling), or β-actin (1:10,000, catalog no.
ab6276; Abcam, Inc, Cambridge, MA) were incubated with mem-
branes overnight at 4°C. Antirabbit HRP-conjugated secondary anti-
bodies (1:5000, catalog no. PI-1000, Vector; Burlingame, CA) or
antimouse HRP-conjugated secondary antibodies (1:5000, catalog
no. 1010-05; Southern Biotech; Birmingham, AL) in 5% evaporated
milk/TBSTwere incubated with membranes for 1 hour at room tem-
perature. Membranes were washed five times for 5 minutes in TBST
after each antibody incubation. Protein bands were visualized using the
Pierce ECL kit (Thermo Fisher Scientific, Rockford, IL).
Apoptosis Assay
Cells were plated in white-walled 96-well tissue culture plates at a
density of 5 × 103 cells per well in 100 μl of medium and allowed to
adhere for 24 hours. Cells were treated in triplicate for 8 to 48 hours
with curcumin at 12.5, 25, and 50 μM with DMSO as the vehicle
control. In separate experiments, Flo-1 and OE33 cell lines were
treated with a combination of curcumin and either 5-FU or CDDP.
Caspase-3 and -7 activity was determined at 8, 24, and 48 hours using
the Caspase–Glo 3/7 assay (catalog no. G8091; Promega, Madison,
WI) as directed by the manufacturer. Briefly, Caspase–Glo 3/7 reagent
was added to each well in a 1:1 ratio and incubated for 30 minutes
before measuring luminescence as relative light units (RLUs) using a
Xenogen IVIS 100 luminometer (Xenogen, Corp, Almeda, CA). Cas-
pase activity was normalized to the cell number using the WST-1 re-
agent in side-by-side assays performed under the same plating density
and conditions.
NF-κB Luciferase Reporter Assay
Flo-1 and OE33 cells were plated at a density of 125,000 cells/
well and transfected with NF-κB-Luc reporter plasmid pNifty-Luc
(InvivoGen, San Diego, CA) using FuGENE 6 (Roche Diagnostics)
at a reagent-plasmid ratio of 16 μl:4 μg in accordance with the man-
ufacturer’s directions. Twenty-four hours after transfection, cells were
treated as described above with curcumin 10 to 100 μM for 48 hours
and 10 ng/ml of TNFα for 5 minutes. At the end of treatment, 1 μl
of 40 mg/ml of D-luciferin (Promega) was added to cells, and bio-
luminescence was monitored using the Xenogen IVIS 100. A gray-
scale image was collected followed by luminescence acquisition, which
was overlaid as a pseudocolor image representing the spatial distribu-
tion of the detected photons emitted from cells. This analysis was
performed using Living Image software (Xenogen). Signal intensity
was quantified as the sum of all detected photon counts within a uni-
form region of interest manually placed over the wells during data
postprocessing. The total numbers of cells in each well were counted,
and NF-κB activity was normalized to cell count before the fold in-
crease was determined.
Statistical Analysis
Data points are reported as experimental averages and error bars rep-
resent SD. Comparisons between experimental groups used the two-
sided Student’s t test, with P < .05 considered statistically significant.
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Results
NF-κB Subunit Gene Expression Increases and
Apoptosis-Related Gene Expression Decreases in EAC
Compared with Barrett Metaplasia
Oligonucleotide expression microarrays were used to evaluate a co-
hort of 46 esophageal tissue samples and revealed a 1.5-fold increase
or higher in REL (33%), RELA (40%), RELB (40%), and NFκB2
(47%) messenger RNA (mRNA) expression in EAC compared with
Barrett metaplasia (P < .05; Figure 1A). In addition, we observed over-
expression of IKK β, γ, and ɛ subunits, components of the upstream
NF-κB activation pathway [27,28], with 9% to 21% greater mean ex-
pression in adenocarcinoma compared with metaplastic Barrett esoph-
agus (P < .01). The oligonucleotide microarray analysis also revealed a
Figure 1. NFκB (relA, relB, and NFκB2), IκB kinase (γ, ɛ), and effector-caspase (3, 6, 7) mRNA expression in the progression from meta-
plastic Barrett esophagus to dysplasia and EAC. (A) HG-U133A (Affymetrix) oligonucleotide microarray analysis of primary tissue sam-
ples from patients with Barrett metaplasia (Barrett, n = 9), low-grade dysplasia (LGD, n = 15), high-grade dysplasia (HGD, n = 7), and
EAC (EAC, n = 15). Individual samples are labeled by tissue type (B, BL, L, H, or T), subject identifier code, and sample number for the
purpose of cross-comparison. Gene expression is labeled as increased (red) or decreased (green). Quantitative real-time PCR analysis of
RELA (B) and CASP7 (C) expression in a panel of primary tissue samples from the oligonucleotide microarray analysis compared with
normal intestinal epithelium. Significant differences of relative quantification were determined using the 2(−ΔΔC (T)) method.
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two-fold or more decrease in CASP3 (30%), CASP6 (47%), and
CASP7 (60%) mRNA expression in EAC compared with Barrett
metaplasia (P < .05; Figure 1A). Reverse transcription–polymerase
chain reaction analysis of RELA and CASP7 confirmed the overall ex-
pression patterns observed in the oligonucleotide microarray data set.
In addition, the EAC cell lines demonstrated similar expression pat-
terns for RELA (Figure 1B) and CASP7 (Figure 1C) when compared
with Barrett metaplasia. To validate that NFκB is activated in EAC, we
Figure 2. Immunohistochemical analysis of (A) IκB and (B) phospho (Ser-32)-IκB in EAC tissues. Paraffin-fixed tissue cores were prepared in
a TMA. Representative sections from subject T-M59-36 (original magnification, ×200) are displayed and indicate focal expression in tumor
glands. This subject also had increased mRNA expression of IKKγ and relB (Figure 1A), consistent with increased NF-κB signaling.
Figure 3. Curcumin dose–response and time course to determine the levels of apoptosis in the EAC cell lines Flo-1 and OE33. Western
blot analysis of PARP cleavage (89-kDa subunit) after a 48-hour treatment with increasing doses of curcumin in both (A) Flo-1 and (B)
OE33 cells. Levels of caspase 3/7 activity as determined by Caspase–Glo 3/7 luminescent-based assays after curcumin treatment at the
indicated doses and with increasing duration of incubation in (C) Flo-1 and (D) OE33 cells. Caspase 3/7 activity was normalized to cell
number as determined by WST-1 proliferation assay. These numbers were then compared with the level of vehicle control at each time
point and expressed as percentage caspase activity (mean % ± SD). Each data point represented three individual wells. Independently
repeated experiments were performed to ensure reproducibility. DMSO was used as the vehicle control in all experiments.
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performed immunohistochemical analysis of a TMA composed of tis-
sue samples of normal, dysplastic, and EAC for the expression of IκB
and its phosphorylated product, P-IκB. Stromal expression of IκB was
observed in 9 (12.3%) of 73 patients, and P-IκB expression was ob-
served in 5 (6.8%) of 73 patients. Representative photomicrographs
from one subject (T-M59-36) indicate focal expression of both IκB
and P-IκB in tumor glands (Figure 2), indicating activation of NF-
κB in this patient’s adenocarcinoma tissue sample.
Curcumin Promotes Apoptosis in EAC Cell Lines
To determine whether caspase-dependent apoptotic activity could be
modulated by curcumin, EAC cell lines Flo-1 and OE33 were treated
with increasing doses of curcumin for 48 hours. Levels of apoptosis, as
determined by immunoblot analysis of PARP expression and cleavage
[29,30], were increased in a dose-dependent fashion up to 50 μM cur-
cumin for both Flo-1 (Figure 3A) and OE33 (Figure 3B). We confirmed
this dose-dependent apoptotic response by luminescent-based caspase 3/
7 assays, which showed more than a four-fold and six-fold increase in
caspase 3/7 activity with a 48-hour treatment with 25 μM curcumin in
Flo-1 (Figure 3C) and OE33 (Figure 3D; P < .05) cells, respectively.
Curcumin Inhibits TNFα-Mediated NF-κB Activation in
EAC Cell Lines
To determine whether the inhibitory effects of curcumin could
be mediated through the NF-κB pathway, we examined IκBα and
phospho-IκBα expression levels and NF-κB luciferase reporter assay
activity after curcumin treatment in the setting of TNFα stimula-
tion. A 5-minute incubation with 10 ng/ml TNFα induced maximal
NF-κB activity as demonstrated by IκBα phosphorylation (data not
shown). Curcumin inhibited TNFα-mediated phosphorylation of
IκB at 25 μM in Flo-1 and at 50 μM in OE33 cell lines, respectively
(Figure 4, A and B). Curcumin inhibited NF-κB reporter gene activ-
ity in a dose-dependent fashion in both Flo-1 (90% at 25 μM) and
OE33 (50% at 50 μM) cell lines (P < .05; Figure 4, C and D). In
Flo-1 cells, maximal caspase 3/7 activity and PARP cleavage was de-
tected with 25 μM curcumin and correlated with almost complete
inhibition of NF-κB activity. The curcumin dose required for 50%
inhibition (45 μM) in OE33 cells was higher than in Flo-1 cells, and
doses as high as 100 μM were required for 90% inhibition. Curcumin
at 25 μM did not inhibit NF-κB activity, yet it induced the maximum
caspase 3/7 activity, suggesting that this induction of apoptosis was
not through NF-κB modulation.
Figure 4. Inhibition of TNFα-induced activation (5 minutes) of NF-κB by curcumin. Flo-1 and OE33 EAC cells were treated with increasing
doses of curcumin that were administered for 12, 24, and 48 hours. TNFα was then added to the medium for 5 minutes followed by
protein isolation for immunoblot analysis of IκB and phospho-IκB in both (A) Flo-1 and (B) OE33 cells. Actin was used as a loading
control. A TNFα-inducible NF-κB-luciferase reporter was transfected into (C) Flo-1 and (D) OE33 cell lines. After treatments with increas-
ing doses of curcumin for 48 hours and TNFα for 5 minutes, D-luciferin was added, and bioluminescence was monitored. Luciferase
reporter experiments were performed in triplicate and expressed as mean expression ± SD relative to TNFα stimulation alone.
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Chemosensitivity to 5-FU and CDDP Increases
with Curcumin
The lethal dose, 50% (LD50) values for Flo-1 and OE33 cell lines
were 25 μg/ml for 5-FU and 20 μg/ml for CDDP (data not shown).
Curcumin enhanced apoptosis in both Flo-1 and OE33 EAC cell lines
when administered in combination with 5-FU, as determined by both
greater caspase-3/7 activity and PARP cleavage (Figure 5). 5-FU doses
of 12.5 μg/ml or greater seemed to have similar levels of cytotoxicity
and caspase 3/7 activity in Flo-1 cells. Although a cytotoxic plateau
effect was also noted in OE33 cells, a dose-dependent response to
Figure 5. Effect of curcumin on 5-FU chemosensitivity in the EAC cell lines Flo-1 and OE33. (A) Levels of apoptosis induced by increas-
ing doses of 5-FU and/or curcumin treatment for 48 hours in Flo-1 and OE33 cells were determined using the Caspase–Glo 3/7 activity
assay. (B) Caspase 3/7 activity was normalized to cell number as determined by WST-1 proliferation assay. These numbers were then
compared with the level of vehicle control and expressed as percentage caspase activity (mean % ± SD). Each data point represented
three individual wells. Immunoblot analyses of PARP cleavage were used to assess apoptosis in (C) Flo-1 cells and (D) OE33 cells that
were treated with increasing doses of 5-FU and/or curcumin for 48 hours. β-Actin was used as a loading control. DMSO was used as the
vehicle control in all experiments. Independently repeated experiments were performed to ensure reproducibility.
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5-FU was observed in both apoptotic assays. Both cell lines seemed
to be sensitive to CDDP treatment in a dose-dependent fashion, with
curcumin having an additive effect for both caspase activity and cel-
lular proliferation (Figure 6). The decrease in caspase 3/7 activation
observed in OE33 cells in response to 20 μg/ml CDDP/curcumin
combinations and high doses of curcumin alone may be due to shifts
toward nonapoptotic mechanisms of cell death such as mitotic catas-
trophe, as has been recently reported [31].
Discussion
Oligonucleotide expression microarray evaluation of a panel of tissue
samples suggested that activation of NF-κB occurs in the neoplastic
progression from Barrett metaplasia to preneoplastic high-grade dys-
plasia and adenocarcinoma. We also observed a concomitant decline
in caspase-3, -6, and -7 gene expression. Taken together, these find-
ings suggest that NF-κB could be an important mediator of tumor
cell survival in EAC, possibly through its inhibitory influence on
Figure 6. Effect of curcumin on CDDP chemosensitivity in the EAC cell lines Flo-1 and OE33. (A) Levels of apoptosis induced by increasing
doses of CDDP (24-hour treatment) and/or curcumin (48-hour treatment) in Flo-1 and OE33 cells were determined using the Caspase–
Glo 3/7 activity assay. (B) Caspase 3/7 activity was normalized to cell number as determined by WST-1 proliferation assay. These numbers
were then compared with the level of vehicle control and expressed as percentage caspase activity (mean % ± SD). Each data point
represented three individual wells. Immunoblot analyses of PARP cleavage were used to assess apoptosis in (C) Flo-1 cells and (D)
OE33 cells that were treated with increasing doses of CDDP (24 hours) and/or curcumin (48 hours). β-Actin was used as a loading control.
DMSO was used as the vehicle control in all experiments. Independently repeated experiments were performed to ensure reproducibility.
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apoptosis. In addition, activation of NF-κB might be an important
mechanism of chemoresistance in the treatment of EAC.
The oligonucleotide expression data reported in this series of tissue
samples are consistent with previous reports of increasing frequency
of NF-κB activation in the neoplastic progression from Barrett meta-
plasia to adenocarcinoma [32,33]. The impact of NF-κB inhibition in
EAC has not been widely reported. Our data demonstrated that ac-
tivation of NF-κB occurred not only in EAC but also in its preneo-
plastic lesion, Barrett esophagus with high-grade dysplasia (Figures 1
and 2). Recently, investigators have demonstrated that NF-κB acti-
vation increases the resistance of Barrett epithelial cells to UV-B–
mediated apoptotic signaling [34], suggesting one mechanism for
increased survival of these precursor lesions as they progress to ade-
nocarcinoma. There is additional indirect evidence regarding the role
for NF-κB activation as a mediator of cellular proliferation. Indeed,
inhibitory RNA to the NF-κB p50 subunit has been shown to reduce
cyclooxygenase 2–dependent cellular proliferation in an EAC cell line
[35]. NF-κB activation may also have a role in epithelial tumor che-
moresistance [36,37], possibly through its induction of cell survival
genes including the inhibitors of apoptosis (IAPs) such as survivin
and X-linked IAP (XIAP) [38].
Pretreatment NF-κB status correlated significantly with overall sur-
vival, disease-free survival, and complete pathologic response, as re-
ported in one retrospective study, in which pretreatment NF-κB
activation was detected in 78% of patients who failed to achieve com-
plete pathologic response and 51% of patients who developed meta-
static esophageal carcinoma [39]. Whether manipulation of NF-κB
activation will be of clinical significance remains to be determined.
A number of pharmacologic agents directed at inhibiting NF-κB
activation are under investigation including curcumin, a naturally
occurring phytopolyphenol pigment that is considered the most ac-
tive component of turmeric [14]. Curcumin has been shown to in-
hibit NF-κB activation during tumor promotion [40] mediated by
phorbol ester, TNF-α, hydrogen peroxide, and cigarette smoke. It
also suppressed cellular proliferation and induced apoptosis through
the inhibition of constitutively activated NF-κB in pancreatic cancer
[8]. In human melanoma cells, curcumin arrested cell cycle progres-
sion at the G2/M phase and induced apoptosis by inhibiting NF-κB
activation [41].
Given these cell cycle effects, curcumin could potentially synergize
with chemotherapeutic agents, inhibiting tumor growth and metas-
tasis. In bladder cancer models, curcumin seemed to potentiate the
apoptotic effects of the chemotherapeutic agents, gemcitabine and
paclitaxel [42]. Furthermore, curcumin suppressed the paclitaxel-
induced NF-κB pathway in breast cancer cells and inhibited me-
tastasis of human breast cancer to the lungs in nude mice [17].
Although curcumin has limited oral bioavailability as a result of
hepatic clearance by glucuronidation and sulfation [43,44], it also
has a low toxicity profile [14,45] and might be suitable for treatment
of upper gastrointestinal malignancies, including esophageal cancers.
Curcumin dose-dependently inhibited NF-κB activity, reduced
cell viability and/or proliferation, and promoted apoptosis in EAC
cell lines. We, therefore, hypothesized that curcumin might sensitize
EAC cell lines to antiproliferative agents such as 5-FU or CDDP, two
“first-line” chemotherapeutic agents for the treatment of EAC. We
observed an enhanced apoptotic response to these chemotherapeutic
agents when either Flo-1 or OE33 cells were concomitantly treated
with curcumin. Curcumin may have enhanced the proapoptotic effects
of these chemotherapeutic agents through the inhibition of NF-κB
activation, or functioned in concert with CDDP, which has been
shown to inhibit NF-κB–dependent transcription, leading to the
down-regulation of XIAP and, in turn, releasing caspase 3 inhibition
[46]. In addition, it may attenuate CDDP-induced NF-κB activa-
tion, as has been shown in several chemoresistant carcinoma cell lines
[47–49]. Whereas curcumin likely has several modes of action, our
data suggest that the combination of curcumin and “first-line” chemo-
therapeutic agents increased apoptosis, as demonstrated by increased
caspase activity and PARP cleavage. Although we have shown that cur-
cumin inhibits NF-κB in EAC cells, other cell signaling pathways in-
cluding Akt, AP-1, or c-Jun N-terminal kinase [14] might also be
significant mediators of this curcumin-induced apoptotic activity. In
fact, the lack of NF-κB inhibition with the dose of curcumin that re-
sulted in maximal caspase 3/7 activity in OE33 cells suggested that
other signaling pathways were also involved.
It has been reported that curcumin can reduce cell survival in a
p53- and caspase-independent manner, possibly through inhibition
of both the NF-κB and AP-1 signaling pathways. O’Sullivan-Coyne
et al. recently showed that curcumin induced apoptosis-independent
cell death in esophageal cancer cells [31]. Specifically, OE33 cells
treated with 15 μM curcumin for 24 hours resulted in 13.4% apopto-
sis and 22.2% mitotic catastrophe. Therefore, the decrease in caspase
activity we observed with 50 μM compared with 25 μM curcumin
may reflect a shift toward mitotic catastrophe at higher doses of cur-
cumin in both OE33 and Flo-1 cells.
In summary, our findings provide further support for the investi-
gation of curcuminoids in the treatment of patients with esophageal
cancer or those with its neoplastic precursor, dysplastic Barrett esoph-
agus. Although efforts to increase systemic bioavailability will likely
be necessary for the treatment of more advanced esophageal cancer,
proximal digestive tract lesions such as Barrett esophagus might be
more amenable to oral-based chemoprevention with curcuminoids.
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